Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients.

ABSTRACT:

Background

Observational studies suggest that loss of skeletal muscle mass (SMM) is associated with chemotherapy-related toxicity, poor quality of life, and poor survival in metastatic colorectal cancer (mCRC) patients. Little is known about the evolution of SMM during palliative systemic therapy. We investigated changes in SMM during various consecutive palliative systemic treatment regimens using repeated abdominal computed tomography scans of mCRC patients who participated in the randomized phase 3 CAIRO3 study.

Methods

In the CAIRO3 study, mCRC patients with stable disease or better after 6 cycles of first-line treatment with capecitabine + oxaliplatin + bevacizumab (CAPOX-B) were randomized between maintenance treatment with capecitabine + bevacizumab (CAP-B) or observa

SUBMITTER: Kurk SA 

PROVIDER: S-EPMC6204584 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature